Pathology‐Driven Diagnosis of Hereditary Leiomyomatosis and Renal Cell Carcinoma: A Clinicopathological and Genetic Analysis of Three Cases Authors: Tomoko Uchiyama, Shunsuke Okazaki, Sayaka Ando, Maiko Takeda, Makito Miyake, Akihiko Yoshizawa Published: 2026 ABSTRACT ABSTRACTIntroductionHereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal dominant disorder characterized by three principal clinical features: cutaneous leiomyomas (cLMs), uterine leiomyomas, and fumarate hydratase (FH)‐deficient renal cell carcinoma (RCC). Although 200–300 families have been identified worldwide, its true prevalence remains unknown.Case PresentationsWe present three HLRCC cases in which detailed pathological examination raised initial clinical suspicion. Cases 1 and 2 presented with advanced RCC exhibiting diverse morphologies. Case 3 presented with multiple painful cLMs and no renal tumors. All three cases were confirmed via germline genetic testing, which revealed distinct FH mutations.ConclusionsThese cases underscore the importance of careful histopathological and immunohistochemical evaluation for the diagnosis of HLRCC. Multidisciplinary discussion integrating clinical, radiological, pathological, and genetic findings is essential for identifying affected families and initiating timely surveillance. Introduction Fumarate hydratase (FH), encoded by the FH gene, is a key enzyme in the tricarboxylic acid cycle for cellular energy metabolism. Germline loss‐of‐function FH mutations cause hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome [1, 2]. While cutaneous leiomyomas (cLMs) exhibit high penetrance, early onset, multiplicity, and frequent pain which may prompt consideration of HLRCC, they may be overlooked or misinterpreted as sporadic lesions without detailed clinicopathological assessment [3, 4]. Similarly, although uterine leiomyomas (uLMs) affect most women with pathogenic FH variants and frequently necessitate surgical intervention before age 30, their high prevalence in the general population means they often do not trigger HLRCC screening [5, 6, 7]. The lifetime risk of developing RCC in patients with HLRCC is approximately 15%, with a median onset age of 36–44 years [8, 9]. Notably, 50%–82% of cases are metastatic at diagnosis or progress rapidly, resulting in a poor prognosis [5, 10]. Previous studies have substantially improved its pathological diagnosis through recognition of its broad histopathological spectrum and using FH and 2‐succinocysteine (2SC) immunohistochemistry (IHC). Nevertheless, a high index of clinical suspicion is essential for diagnosing the underlying hereditary syndrome [11, 12]. Cases Presentation Case 1 A 51‐year‐old man with no notable medical history presented with low‐grade fever; family history revealed his sister died of uterine leiomyosarcoma at the age of 40. He showed no evidence of multiple cLMs. Imaging suggested RCC (pT3aN1M1, Stage IV) with pulmonary, hepatic, and lymph node metastases, and a left nephrectomy was performed. Histopathological findings are shown in Figure 1. In IHC, the tumor cells were positive for vimentin, PAX8, and AMACR, with focal positivity for GATA3, but negative for CK7, CK20, CD10, CA9, TFE3, TFEB, and ALK. SDHB expression was retained. Reduced FH expression and diffuse strong 2SC positivity confirmed FH‐deficient RCC, and the attending physician was informed of the possibility of HLRCC, prompting further genetic evaluation. Given the strong suspicion of HLRCC and the patient's already advanced Stage IV disease, comprehensive genomic profiling (CGP) was prioritized. CGP of the tumor‐derived DNA (FoundationOne_CDx) identified the FH c.584T>C [p.Met195Thr] variant. Subsequent single‐site germline testing using peripheral blood–derived DNA detected the same FH c.584T>C pathogenic variant, confirming its germline origin and establishing a diagnosis of HLRCC. Despite initial partial reduction of metastatic lesions with nivolumab and ipilimumab, new adrenal and bone metastases developed, and the patient died 14 months post‐surgery. (A) Summary of the macroscopic appearance, histopathological, and IHC findings in Case 1. (a) Gross findings. A solid white mass measuring 65 × 55 mm, with a renal hilar lymph node nodule suspicious for metastasis. (b–e) Hematoxylin and eosin staining. (b) Tubular pattern. (c) Reticular pattern. (d) Papillary pattern. (e) Lymph node metastases showing tumor cells with an invasive micropapillary pattern, as seen in other organs. (f) FH IHC is interpreted as weakly positive. (B) Pedigree of Case 1. Case 2 A 48‐year‐old woman presented with right lower abdominal pain. Her mother developed uLMs in her 20s. Imaging revealed a renal mass with focal cystic changes, and the patient underwent right nephrectomy with lymph node dissection. Histopathological findings are shown in Figure 2. The IHC findings were comparable to those of Case 1 and supported a diagnosis of FH‐deficient RCC (pT3aN1M0, Stage III). DNA extracted from formalin‐fixed paraffin‐embedded tumor tissues was analyzed for FH mutations (all exons) using our in‐house NGS assay on the MiniSeq platform (Illumina, San Diego, CA, USA), and no single‐nucleotide variants or small insertions/deletions were detected. Further genetic evaluation using peripheral blood via Multiplex ligation‐dependent probe amplification (MLPA) identified c.(267 + 1_268–1)_(1390 + 1_1391–1)del (exons 3–9 deletion), confirming HLRCC. Retrospective FH IHC of the archived pathological specimen from the uLM resected 4 years earlier showed loss of FH expression. The painless cutaneous nodules, present for approximately 20 years, were excised after RCC surgery and diagnosed as piloleiomyoma, with loss of FH expression (Figure 3A. Panels a and b show uLMs, whereas c and d show cLMs). The patient received adjuvant pembrolizumab but developed lung metastases 16 months post‐surgery. (A) Summary of the macroscopic appearance, histopathological, and IHC findings in Case 2. (a) Gross findings showing a solid white mass (60 × 45 mm) with cystic changes. (b–e) Hematoxylin and eosin staining. (b) Papillary pattern. (c) Tubular and microcystic patterns. (d) Sessile papillary to micropapillary architecture. (e) Large eosinophilic nucleoli with perinucleolar halo. (f) FH IHC showing complete loss of expression. (B) Pedigree of Case 2. The patient received adjuvant pembrolizumab but developed lung metastases 16 months post‐surgery. (A) Histopathological and IHC findings of cLM and uLM in Case 2 and cLM in Case 3. (a) ULM from Case 2 shows typical histological features on hematoxylin and eosin staining (H&E). (b) FH IHC staining of the uLM from Case 2 demonstrates loss of FH expression in the tumor cells, and the intervening vascular endothelial cells show preserved positivity (serving as an internal positive control). (c) CLM from Case 2 on H&E. (d) FH IHC staining of cLM from Case 2 shows the absence of FH expression in the tumor cells; the inset (lower left) shows a higher‐power view. (e) cLM from Case 3 on H&E. (f) FH IHC staining of cLM from Case 3 shows loss of FH expression in the tumor cells; the inset (lower left) shows a higher‐power view. (B) Pedigree of Case 3. Case 3 A 54‐year‐old man presented with a 5‐year history of multiple painful cutaneous nodules on the forehead and neck. His mother had a history of uLM and died of RCC. Two lesions were excised at our institution; histopathology revealed well‐circumscribed dermal tumors composed of interlacing bundles of spindle cells with eosinophilic cytoplasm and elongated, blunt‐ended nuclei, consistent with piloleiomyoma. IHC showed complete loss of FH expression, raising suspicion for HLRCC (Figure 3A e,f). Subsequent germline testing using peripheral blood identified a heterozygous FH missense mutation, c.824G>A (p.Gly275Glu), confirming HLRCC. Urologic screening showed no renal tumors, and the patient remains under outpatient follow‐up. Discussion The broad and heterogeneous clinical spectrum of HLRCC, ranging from asymptomatic individuals to patients with severe cutaneous, uterine, and renal manifestations that may overlap with sporadic tumors in routine practice, likely leads to underdiagnosis, and its true prevalence remains unknown [4, 5, 13]. In Japan, 19 HLRCC families were reported between 2007 and 2020 [14]. Excluding one case with an FH c.77C>T variant now classified as benign or likely benign, a total of 37 HLRCC cases have been documented in Japan. (Table S1). Histopathologically, FH‐deficient RCC is characterized by heterogeneous architectural patterns and distinctive prominent eosinophilic nucleoli [9, 15]. Our two RCC cases demonstrated diverse morphologies, including micropapillary, cystic, tubular, reticular, and single‐cell growth patterns. Notably, papillary structures were not prominent in Case 2, suggesting that FH‐deficient RCC should be considered in RCCs with heterogeneous architectural patterns, thereby prompting proactive IHC staining for FH and 2SC. Combined IHC staining for FH and 2SC is useful for the pathological diagnosis of FH‐deficient RCC, with a reported sensitivity of 100% and a specificity of 91.7% [16]. However, while FH expression loss correlates strongly with non‐synonymous mutations, such as deletions, frameshift mutations, and truncating mutations, it is less consistent with single‐nucleotide variants or small insertions/deletions [15]. Most missense mutations are thought to retain partial enzymatic activity [17], potentially explaining the incomplete loss of FH expression, as demonstrated in Case 1, and highlighting the need for careful interpretation of FH IHC results. Case 2 highlights the importance of performing deletion/duplication or copy‐number analysis when FH‐deficient RCC is strongly suspected based on the pathological findings. Although the risk of RCC in carriers of FH variants younger than 20 years is estimated at only 1%–2% [8], the prognosis is often poor once RCC develops, and no standard systemic treatment has been established [18]. Therefore, identifying HLRCC families, providing genetic counseling, and initiating appropriate surveillance from childhood is critically important. Case 2 highlights potentially missed opportunities for earlier recognition of HLRCC. Although the patient underwent uterine surgery and had multiple cLMs before developing advanced RCC, HLRCC was not suspected until RCC was diagnosed. In Case 3, multiple cLMs prompted FH IHC and confirmatory genetic testing [19]. Ouchene et al. reported that cLMs had a sensitivity and specificity of 92.6% and 98.0%, respectively, for HLRCC diagnosis, indicating that even solitary or few cLMs should be considered major diagnostic criteria for HLRCC [3]. Although no characteristic histopathological features have been established based on hematoxylin–eosin staining alone [4], HLRCC should be considered when evaluating cLMs, prompting proactive IHC and detailed assessment of family and medical history. This case report describes three patients with HLRCC in whom pathological findings prompted HLRCC suspicion, multidisciplinary discussion, and germline genetic testing, highlighting the importance of integrating clinical, radiological, pathological, and genetic findings for diagnosis. Ethics Statement The protocol for this research project has been approved by a suitably constituted Ethics Committee of the institution, and it conforms to the provisions of the Declaration of Helsinki (Ethics Review Committee of Nara Medical University, approval No. 4266). All informed consent was obtained from the subjects. Consent Informed consent was obtained from the patients and their families. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Table S1: HLRCC families reported in Japan (2007–2026).